Leukemia

ChemGenex reports on Ceflatonin/Gleevec therapy in CML patients resistant to Gleevec alone

Published in Cancer Law Weekly, January 13th, 2007

ChemGenex Pharmaceuticals (CXS; CXSP) announced the presentation of new phase 2 clinical data supporting the use of Ceflatonin (homoharringtonine or HHT) in combination with imatinib mesylate (Gleevec) to treat chronic myeloid leukemia (CML) patients who have developed resistance to Gleevec and other tyrosine kinase inhibitors.

The study was undertaken by Dr. Jorge Cortes, Dr. Hagop Kantarjian and colleagues from the M.D. Anderson Cancer Center in Houston, Texas and data were presented in a poster at the American Society of Hematology (ASH) Annual Meeting held in Orlando, Florida. The presentation described the effects of the Ceflatonin and Gleevec combination therapy...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Law Weekly

Source: Cancer Law Weekly (2007-01-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry